Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 632 across all filing types
Latest filing 2022-04-27 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
江苏浩欧博生物医药股份有限公司关于调整2022年限制性股票激励计划首次授予部分激励对象名单及授予数量的公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding adjustments to the 2022 restricted stock incentive plan, including the list of initial grant recipients and the number of shares granted. It details board and supervisory approvals, legal opinions, and independent financial advisor opinions related to the stock incentive plan. The content focuses on changes in stock incentive allocations and related corporate governance procedures. This type of document is a formal announcement about share-based compensation plans and adjustments, which fits the category of Share Issue/Capital Change (SHA) because it involves issuance and allocation of restricted stock as part of an incentive plan. The document is not a full financial report, earnings release, or management discussion, nor is it a proxy or voting result announcement. It is also not a regulatory filing or report publication announcement since it contains substantive information about the stock incentive plan adjustments. Therefore, the best classification is SHA with high confidence.
2022-04-27 Chinese
江苏浩欧博生物医药股份有限公司第二届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the meeting held on April 26, 2022, including approval of adjustments to a 2022 restricted stock incentive plan, the initial grant of restricted stock, and approval of the company's 2022 first quarter report. The document references the 2022 first quarter report but does not contain the report itself or substantive financial data. It is a formal announcement of meeting resolutions and approvals, not the report or financial statements. The document length is short (1803 characters), and it directs readers to the Shanghai Stock Exchange website for the full report. Therefore, it is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board resolutions and references other filings but does not contain the full report or detailed financial data itself.
2022-04-27 Chinese
江苏浩欧博生物医药股份有限公司关于向激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the initial grant of restricted shares under a stock incentive plan by Jiangsu Haobo Biopharmaceutical Co., Ltd. It details the grant date, number of shares, recipients, approval process, legal and financial opinions, and compliance with regulatory requirements. The content focuses on the company's equity incentive plan and the granting of restricted stock to employees and management. This type of document is a formal announcement about a capital change related to share issuance to employees as part of an incentive plan. It is not a full financial report, audit report, or management discussion, nor is it a proxy or voting result announcement. It fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes such as stock grants or stock options.
2022-04-27 Chinese
江苏浩欧博生物医药股份有限公司第二届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Jiangsu Haoubo Biopharmaceutical Co., Ltd. It details the decisions made at the 16th meeting of the second board of directors, including approval of adjustments to a 2022 restricted stock incentive plan, the initial grant of restricted stock, and approval of the 2022 first quarter report. The document includes voting results and references to related announcements on the Shanghai Stock Exchange website. The content focuses on board decisions and approvals rather than presenting the full quarterly report itself. The document length is short (1784 characters) and it references the first quarter report rather than containing it. Therefore, this is a Board/Management Information announcement about board resolutions and approvals, not the actual quarterly report (IR) or other financial report. Hence, the appropriate classification is MANG (Board/Management Information).
2022-04-27 Chinese
江苏浩欧博生物医药股份有限公司2022年限制性股票激励计划首次授予部分激励对象名单（截止授予日）
Share Issue/Capital Change Classification · 95% confidence The document is titled as a list of recipients for a 2022 restricted stock incentive plan by Jiangsu Haoyoubo Biopharmaceutical Co., Ltd. It details the allocation of restricted stock to various employees and executives, including percentages of total shares and reserved portions. The content focuses on stock incentive plan allocations and related disclosures, which is characteristic of announcements related to share issues or capital changes. The document is relatively short (1295 characters) and does not contain financial statements or detailed financial performance data. It is not an annual or interim report, nor an earnings release or management discussion. It is not a proxy solicitation or voting result announcement. The content fits best with a Share Issue/Capital Change announcement, as it relates to the issuance of restricted stock under an incentive plan.
2022-04-27 Chinese
江苏浩欧博生物医药股份有限公司监事会关于公司2022年限制性股票激励计划首次授予部分激励对象名单的核查意见（截止授予日）
Capital/Financing Update Classification · 95% confidence The document is a supervisory board opinion on the company's 2022 restricted stock incentive plan, specifically the verification of the initial grant list of incentive recipients. It references compliance with company law, securities law, stock exchange listing rules, and internal company regulations. The content focuses on the approval and verification of stock incentive recipients and grant details, including the grant date and price. This is related to the company's capital and financing activities, specifically equity incentives and stock grants. The document is not a full financial report, earnings release, or management discussion, nor is it a regulatory announcement or voting result. It fits best under Capital/Financing Update (CAP) as it deals with stock incentive plan grants and related capital changes.
2022-04-27 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.